In vitro and in vivo evaluation of a hydrogel-based prototype transdermal patch system of alfuzosin hydrochloride

Pharmaceutical Development and Technology

Volumn 17, Issue 2, 2012, Pages 158-163

  Nair, Anroop B ^a   Kiran Vaka, Siva Ram ^b   Gupta, Sumit ^a   Repka, Michael A ^b   Murthy, S Narasimha ^b  

^a MAHARISHI MARKANDESHWAR DEEMED TO BE UNIVERSITY   (India)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Alfuzosin; Chemical enhancers; Iontophoresis; Pharmacokinetics; Transdermal

Indexed keywords

ALFUZOSIN; MACROGOL; MENTHOL; METHIONINE; MYRISTIC ACID ISOPROPYL ESTER; PROPYLENE GLYCOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; IONTOPHORESIS; MAXIMUM PLASMA CONCENTRATION; MEMBRANE TRANSPORT; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RAT; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ANIMALS; EQUIPMENT DESIGN; HUMANS; HYDROGEL; IONTOPHORESIS; MALE; PROSTATIC HYPERPLASIA; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; SKIN; SKIN ABSORPTION; TRANSDERMAL PATCH;

EID: 84863152831     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2010.522585     Document Type: Article

References (27)

1. Carbone DJ Jr, Hodges S. Medical therapy for benign prostatic hyperplasia: Sexual dysfunction and impact on quality of life. Int J Impotence Res 2003;15:299-306.
2. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-479.
3. Roehrborn CG, Rosen RC. Medical therapy options for aging men with benign prostatic hyperplasia: Focus on alfuzosin 10 mg once daily. Clin Interv Aging 2008;3:511-524.
4. Tammela T. Benign prostatic hyperplasia. Practical treatment guidelines. Drugs Aging 1997;10:349-366.
5. Lepor H. Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol 2007;9:181-190.
6. Giuliano F. Lower urinary tract symptoms and sexual dysfunction: A common approach. BJU Int 2008;101:22-26.
7. Wilde MI, Fitton A, McTavish D. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs 1993;45:410-429.
8. Lee M. Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia. Am J Health Syst Pharm 2003;60:1426-1439.
9. Weiner DM, Lowe FC. Alfuzosin for the management of benign prostate hyperplasia. Expert Opin Pharmacother 2003;4: 2057-2063.
10. Vallancien G, Emberton M, Alcaraz A, Matzkin H, Van Moorselaar RJ, Hartung R, Harving N, Elhilali M. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: A 3-year experience in real-life practice. BJU Int 2008;101:847-852.
11. Kongkanand A, Chodchoy V, Lojanapiwat B, Pumpaisanchai S, Ratana-Olarn K, Sae-Tang P, Taweemonkongsap T. Safety and efficacy of a prolonged-release formulation of alfuzosin 10 mg once daily in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. J Med Assoc Thai 2009;92:969-978.
12. Zabala S, Thomson C, Valdearcos S, Gascón A, Pina MA. Alfuzosininduced hepatotoxicity. J Clin Pharm Ther 2000;25:73-74.
13. Yolcu OF, Köklü S, Köksal AS, Yüksel O, Beyazit Y, Basar O. Alfuzosin-induced acute hepatitis in a patient with chronic liver disease. Ann Pharmacother 2004;38:1443-1445.
14. Kim SY, Kim BH, Dong SH, Kim HJ, Chang YW, Chang R, Kim YW. Alfuzosin-induced acute liver injury. Korean J Hepatol 2007;13:414-418.
15. Barry BW. Mode of action of penetration enhancers in human skin. J Control Release 1987;6:85-97.
16. Sinha VR, Kaur MP. Permeation enhancers for transdermal drug delivery. Drug Dev Ind Pharm 2000;26:1131-1140.
17. Kandavilli S, Nair V, Panchagnula R. Polymers in transdermal drug delivery systems. Pharm. Technol 2002;26:62-80.
18. Valenta C, Auner BG. The use of polymers for dermal and transdermal delivery. Eur J Pharm Biopharm 2004;58:279-289.
19. Hoare TR, Kohane DS. Hydrogels in drug delivery: Progress and challenges. Polymer 2008;49:1993-2007.
20. Siegel SJ, Neill CO, Dube LM, Kaldeway P, Morris R, Jackson D, Sebree T. A unique iontophoretic patch for optimal transdermal delivery of sumatriptan. Pharm Res 2007;24:1919-1926.
21. Banga AK, Chien YW. Hydrogel-based iontophoretic delivery devices for transdermal delivery of peptide/protein drugs. Pharm Res 1993;10:697-702.
22. Phipps JB, Padmanabhan RV, Lattin GA. Iontophoretic delivery of model inorganic and drug ions. J Pharm Sci 1989;78:365-369.
23. Fang J, Huang Y, Wu P, Tsai Y. Transdermal iontophoresis of sodium nonivamide acetate II: Optimization and evaluation on solutions and gels. Int J Pharm 1996;145:175-186.
24. Kanikkannan N. Iontophoresis based transdermal delivery systems. Biodrugs 2002;16:339-347.
25. Murthy SN, Sen A, Hui SW. Surfactant-enhanced transdermal drug delivery by electroporation, J Control Release 2004;98:307-315.
26. Murthy SS, Vaka SRK, Mathur SK, Murthy, SN. Noninvasive transcutaneous sampling of glucose by Electroporation. J Diabetes Sci Technol 2008;2:250-254.
27. Singh P, Maibach HI. Iontophoresis in drug delivery: Basic principles and applications. Crit Rev Ther Drug Carrier Syst 1994;11:161-213.